OBJECTIVES: Androgens, especially dihydrotestosterone, have been postulated to modify the risk of prostate cancer. 3-Beta-hydroxysteroid dehydrogenase1 (HSD3B1) and uridine diphosphate-glucuronosyltransferase 2B17 (UGT2B17) are enzymes that inactivate dihydrotestosterone in the prostate and may affect dihydrotestosterone concentration in prostatic tissue. The purpose of this study was to determine whether polymorphisms in HSD3B1 and UGT2B17 increase the risk of prostate cancer. METHODS: In a case-control study of 356 patients with incident primary prostate cancer and 363 age-matched controls, the frequencies of HSD3B1 N367T and UGT2B17 null polymorphisms in genomic DNA were compared between the patients and controls. RESULTS: No evidence was found for a main effect of the HSD3B1 codon 367 polymorphism on prostate cancer risk. However, among white men with family history of prostate cancer, the HSD3B1 367Thr allele was positively associated with prostate cancer (odds ratio 3.0, 95% confidence interval 1.0 to 9.2). A significant association was observed between the UGT2B17 null polymorphism and prostate cancer risk (odds ratio 1.7, 95% confidence interval 1.03 to 2.9). An association with the UGT2B17 null polymorphism was further elevated (odds ratio 2.7, 95% confidence interval 1.1 to 6.5) among individuals with HSD3B1 Asn/Asn genotype. CONCLUSIONS: These results suggest that the HSD3B1 N367T and UGT2B17 null polymorphisms may modify the risk of prostate cancer, particularly among men with a family history of the disease.
OBJECTIVES: Androgens, especially dihydrotestosterone, have been postulated to modify the risk of prostate cancer. 3-Beta-hydroxysteroid dehydrogenase1 (HSD3B1) and uridine diphosphate-glucuronosyltransferase 2B17 (UGT2B17) are enzymes that inactivate dihydrotestosterone in the prostate and may affect dihydrotestosterone concentration in prostatic tissue. The purpose of this study was to determine whether polymorphisms in HSD3B1 and UGT2B17 increase the risk of prostate cancer. METHODS: In a case-control study of 356 patients with incident primary prostate cancer and 363 age-matched controls, the frequencies of HSD3B1N367T and UGT2B17 null polymorphisms in genomic DNA were compared between the patients and controls. RESULTS: No evidence was found for a main effect of the HSD3B1 codon 367 polymorphism on prostate cancer risk. However, among white men with family history of prostate cancer, the HSD3B1 367Thr allele was positively associated with prostate cancer (odds ratio 3.0, 95% confidence interval 1.0 to 9.2). A significant association was observed between the UGT2B17 null polymorphism and prostate cancer risk (odds ratio 1.7, 95% confidence interval 1.03 to 2.9). An association with the UGT2B17 null polymorphism was further elevated (odds ratio 2.7, 95% confidence interval 1.1 to 6.5) among individuals with HSD3B1 Asn/Asn genotype. CONCLUSIONS: These results suggest that the HSD3B1N367T and UGT2B17 null polymorphisms may modify the risk of prostate cancer, particularly among men with a family history of the disease.
Authors: Delores J Grant; Cathrine Hoyo; Shannon D Oliver; Leah Gerber; Katie Shuler; Elizabeth Calloway; Alexis R Gaines; Megan McPhail; Jonathan N Livingston; Ricardo M Richardson; Joellen M Schildkraut; Stephen J Freedland Journal: Genet Test Mol Biomarkers Date: 2012-10-25
Authors: Bao-Li Chang; Elaine Spangler; Stephen Gallagher; Christopher A Haiman; Brian Henderson; William Isaacs; Marnita L Benford; LaCreis R Kidd; Kathleen Cooney; Sara Strom; Sue Ann Ingles; Mariana C Stern; Roman Corral; Amit D Joshi; Jianfeng Xu; Veda N Giri; Benjamin Rybicki; Christine Neslund-Dudas; Adam S Kibel; Ian M Thompson; Robin J Leach; Elaine A Ostrander; Janet L Stanford; John Witte; Graham Casey; Rosalind Eeles; Ann W Hsing; Stephen Chanock; Jennifer J Hu; Esther M John; Jong Park; Klara Stefflova; Charnita Zeigler-Johnson; Timothy R Rebbeck Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-11-11 Impact factor: 4.254
Authors: Timothy R Rebbeck; Susan S Devesa; Bao-Li Chang; Clareann H Bunker; Iona Cheng; Kathleen Cooney; Rosalind Eeles; Pedro Fernandez; Veda N Giri; Serigne M Gueye; Christopher A Haiman; Brian E Henderson; Chris F Heyns; Jennifer J Hu; Sue Ann Ingles; William Isaacs; Mohamed Jalloh; Esther M John; Adam S Kibel; Lacreis R Kidd; Penelope Layne; Robin J Leach; Christine Neslund-Dudas; Michael N Okobia; Elaine A Ostrander; Jong Y Park; Alan L Patrick; Catherine M Phelan; Camille Ragin; Robin A Roberts; Benjamin A Rybicki; Janet L Stanford; Sara Strom; Ian M Thompson; John Witte; Jianfeng Xu; Edward Yeboah; Ann W Hsing; Charnita M Zeigler-Johnson Journal: Prostate Cancer Date: 2013-02-13
Authors: Adriana C Vidal; Cocoa Tucker; Joellen M Schildkraut; Ricardo M Richardson; Megan McPhail; Stephen J Freedland; Cathrine Hoyo; Delores J Grant Journal: BMC Cancer Date: 2013-11-22 Impact factor: 4.430